Market Focus On PharmaPoint: Atrial Fibrillation Drug Forecast and Market Analysis to 2023


The Report PharmaPoint: Atrial Fibrillation – Global Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially, an antiarrhythmic drug for rhythm control.

All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.

In contrast, despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower. Two potential antiarrhythmic drugs are in late-stage development and are forecast to enter the market within the next decade: Gileads ranolazine/dronedarone and ChanRxs vanoxerine.

View Report At :


Key Questions Answered

  • The anticoagulant market for stroke prevention in AF has become increasingly crowded. How will the drug treatment landscape for AF change? Which of the NOACs will become the market leader over the next ten years? What are the key drivers and barriers to this change?

  • The AF market is marked by the presence of a number of unmet needs. What are the main unmet needs in the treatment of AF? Will the drugs under development fulfil the unmet needs of the AF market?

  • Will any of the late-stage antiarrhythmic drugs make a significant impact on the AF market? Which of these drugs will have the highest peak sales at the end of the forecast period, and why?

Key Findings

  • The major driver for the growth of the AF market will be the continued uptake of the NOACs for the prevention of stroke in patients with AF. Due to the advances that the NOACs provide in terms of improved safety and the lack of a need for routine monitoring, NOAC uptake will continue to increase, taking market share away from vitamin K antagonists, such as warfarin.

  • The second major driver will be the approval and launch of the first antidotes for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent in the event of uncontrolled bleeding, and will increase overall uptake.

  • Despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower due to the high risk involved in developing these drugs. Barriers to growth include the requirement for large, costly, and comprehensive clinical trials to support regulatory approval of cardiovascular drugs, which will deter drug developers wanting to enter the AF market. Widely available generic antiarrhythmic drugs will also make it difficult for any novel rhythm control agents to gain reimbursement and wider uptake.

Download Sample copy of this Report at:


  • Overview of AF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

  • Annualized AF therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2013, forecast for ten years to 2023.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AF therapeutics market.

  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

  • Analysis of the current and future market competition in the global AF therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Additionally a list of acquisition targets included in the pipeline product company list.

  • Develop business strategies by understanding the trends shaping and driving the global AF therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AF therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track drug sales in the global AF therapeutics market from 2013-2023.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 12

1.1 List of Tables 19

1.2 List of Figures 24

2 Introduction 26

2.1 Catalyst 26

2.2 Related Reports 27

2.3 Upcoming Related Reports 27

3 Disease Overview 28

3.1 Etiology and Pathophysiology 28

3.1.1 Etiology 28

3.1.2 Pathophysiology 29

3.2 Symptoms 30

3.3 Classification of Atrial Fibrillation 31

3.4 Prognosis 32

4 Epidemiology 33

4.1 Disease Background 33

4.2 Risk Factors and Comorbidities 34

4.3 Global Trends 36

4.4 Forecast Methodology 38

4.4.1 Sources Used 40

4.4.2 Forecast Assumptions and Methods 46

4.4.3 Sources Not Used 51

4.5 Epidemiological Forecast for Atrial Fibrillation (2013-2023) 52

4.5.1 Diagnosed Prevalent Cases of Atrial Fibrillation 52

4.5.2 Age-Specific Diagnosed Prevalent Cases of Atrial Fibrillation 53

4.5.3 ***-Specific Diagnosed Prevalent Cases of Atrial Fibrillation 55

4.5.4 Age-Standardized Diagnosed Prevalence of Atrial Fibrillation 57

4.5.5 Diagnosed Prevalent Cases of Atrial Fibrillation by Clinical Subtypes 59

4.6 Discussion 60

4.6.1 Epidemiological Forecast Insight 60

4.6.2 Limitations of the Analysis 62

4.6.3 Strengths of the Analysis 63

5 Disease Management 64

5.1 Diagnosis and Treatment Overview 64

5.1.1 Diagnosis 64

5.1.2 Treatment Guidelines and Leading Prescribed Drugs 66

5.1.3 Clinical Practice 68

5.2 US 82

5.3 France 84

5.4 Germany 86

5.5 Italy 88

5.6 Spain 90

5.7 UK 92

5.8 Japan 94

Follow us on LinkedIn:

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074